GlassScriptPhysician profile
Stefanie N Xenakis
NPI 1801316831
$7,278.03
in general payments reported to CMS, 2019-2025
36 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $358 · 2023: $2,462 · 2024: $2,622 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,424 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,423.53 |
| Education | $112.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.28 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $660.33 | 2022-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $626.22 | 2022-2025 | Caplyta |
| Corium, LLC | $539.44 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $521.69 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $464.33 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $364.78 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $335.64 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $294.31 | 2021-2025 | Spravato |
| Tris Pharma INC | $264.50 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $259.60 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $238.32 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $237.23 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $219.59 | 2023-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $210.35 | 2022-2025 | Adzenys Xr-Odt |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Xenakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.